JDRF and Sanofi Attempt to Reshape Insulin Therapy

JDRF and Sanofi have announced a $4.6 million, three-year initiative to expand development of insulins that require fewer injections and dermal patch-delivered insulin. In both cases, it’s hoped that the insulin delivered will be able to respond automatically to changes in blood sugar levels and other body metabolism signals.

Read more

Posted in Type I Medical Research